Date: November 12, 2009
URL: =20
http://finance.yahoo.com/news/CORRECTION-Holzer-Holzer-iw-766428846.html
Holzer Holzer & Fistel, LLC announces that it has filed a class
action lawsuit on behalf of investors in Hemispherx Biopharma, Inc.
-------------------------------------------------------------------
ATLANTA, GA--(Marketwire - 11/12/09) - In the news release, "Holzer
Holzer & Fistel, LLC Announces That It Has Filed a Class Action
Lawsuit on Behalf of Investors in Hemispherx Biopharma, Inc.," issued
earlier today by Holzer Holzer & Fistel, LLC, we are advised by the
company that the lead plaintiff deadline date in the second paragraph
should read "January 11, 2010" rather than "January 11, 2009" as
originally issued. Complete corrected text follows.
Holzer Holzer & Fistel, LLC Announces That It Has Filed a Class Action
Lawsuit on Behalf of Investors in Hemispherx Biopharma, Inc.
ATLANTA, GA -- November 12, 2009 -- Holzer Holzer & Fistel, LLC announces
that it has filed a class action lawsuit in the United States District
Court for the Eastern District of Pennsylvania on behalf of purchasers of
Hemispherx Biopharma, Inc. ("Hemispherx" or the "Company") (AMEX:HEB -
News) who purchased shares between February 18, 2009 and October 30, 2009,
inclusive (the "Class Period"). The lawsuit alleges that Hemispherx
misrepresented the status of its experimental drug Ampligen. Specifically,
the complaint alleges that, among other things, the Company failed to
disclose that requests for information from the Food and Drug
Administration would delay possible FDA approval of Ampligen by at least
several months.
If you purchased shares of Hemispherx common stock during the Class Period,
you have the legal right to petition the Court to be appointed a "lead
plaintiff." A lead plaintiff is a representative party that acts on behalf
of other class members in directing the litigation. Any such request must
satisfy certain criteria and be made no later than January 11, 2010. Any
member of the purported class may move the Court to serve as lead
plaintiff through counsel of their choice, or may choose to do nothing and
remain an absent class member. If you are a Hemispherx investor and would
like to discuss a potential lead plaintiff appointment, or your rights and
interests with respect to the lawsuit, you may contact Michael I. Fistel,
Jr., Esq., or Marshall P. Dees, Esq. via email at mfistel@holzerlaw.com,
or mdees@holzerlaw.com, or via toll-free telephone at (888) 508-6832.
Holzer Holzer & Fistel, LLC is an Atlanta, Georgia law firm that dedicates
its practice to vigorous representation of shareholders and investors in
litigation nationwide, including shareholder class action and derivative
litigation. More information about the firm is available through its
website, http://www.holzerlaw.com and upon request from the firm.
--------
(c) 2009 MarketWire
----- Einde doorgestuurd bericht -----
----- Einde doorgestuurd bericht -----
---------------------------------------------
Send posts to CO-CURE@listserv.nodak.edu
Unsubscribe at http://www.co-cure.org/unsub.htm
---------------------------------------------
Co-Cure's purpose is to provide information from across the spectrum of
opinion concerning medical, research and political aspects of ME/CFS and/or
FMS. We take no position on the validity of any specific scientific or
political opinion expressed in Co-Cure posts, and we urge readers to
research the various opinions available before assuming any one
interpretation is definitive. The Co-Cure website <www.co-cure.org> has a
link to our complete archive of posts as well as articles of central
importance to the issues of our community.
---------------------------------------------
